The impact of multiple sclerosis on life expectancy (the experience of the Republic of Bashkortostan)
O. V. Lyutov,
M. A. Kutlubaev,
U. Sh. Kuzmina,
N. F. Akhmetgaleeva,
I. D. Talipova,
K. Z. Bakhtiyarova https://doi.org/10.14412/2074-2711-2026-1-49-56
Abstract
The results of the first analysis of life expectancy, mortality, and causes of death in patients with multiple sclerosis (MS) in the Republic of Bashkortostan (RB) are presented.
Objective: to study life expectancy indicators and mortality patterns among MS patients in the RB.
Material and methods. The assessment of indicators was based on data from the Republican Centre for MS (RCMS) registry at the G. G. Kuvatov Republican Clinical Hospital for the period 2005–2023. During this period, 2,967 patients (10,303 person-years) were treated at the RCMS, of whom 297 died. Life expectancy was assessed using the Gehan–Breslow test. Standardised mortality rates (SMR) were calculated. The causes of death were determined based on information from the Republican Medical Information and Analytical System of the RB.
Results. In more than 70 % of cases, the cause of death may be related to MS and its complications. The overall SMR rate among patients was 1.92. The average life expectancy of MS patients is 19.1 years shorter than that of the general population. The median survival rate of patients was 32 years on average. The average life expectancy for women with MS was significantly higher than for men.
Conclusion. In the RB, the presence of MS increases the risk of premature death and reduces the patient's life expectancy. The indicators studied in the republic reflect global patterns and trends.
Supporting agencies: The investigation has not been sponsored
About the Authors
O. V. Lyutov
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
450008; 3, Lenina St.; Ufa
Competing Interests:
There are no conflicts of interest
M. A. Kutlubaev
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
450008; 3, Lenina St.; Ufa
Competing Interests:
There are no conflicts of interest
U. Sh. Kuzmina
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
450008; 3, Lenina St.; Ufa
Competing Interests:
There are no conflicts of interest
N. F. Akhmetgaleeva
Republican Children's Clinical Hospital
Russian Federation
Competing Interests:
Russian Federation
450106; 98, Stepana Kuvykina St.; Ufa
Competing Interests:
There are no conflicts of interest
I. D. Talipova
G.G. Kuvatov Republican Clinical Hospital
Russian Federation
Competing Interests:
Russian Federation
450005; 132, Dostoevskogo St.; Ufa
Competing Interests:
There are no conflicts of interest
K. Z. Bakhtiyarova
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Klara Zakievna Bakhtiyarova
450008; 3, Lenina St.; Ufa
Competing Interests:
There are no conflicts of interest
References
1. Leadbetter R, MacAskill M, Myall DJ, et al. Multiple sclerosis mortality in New Zealand: a nationwide prospective study. J Neurol Neurosurg Psychiatry. 2023;94(7):511-7. doi: 10.1136/jnnp-2022-330582
2. Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis. Neurology. 2013;81(2):184-92. doi: 10.1212/WNL.0b013e31829a3388
3. Sandi D, Zsiros V, Füvesi J, et al. Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013. J Neurol Sci. 2016;367:329-32. doi: 10.1016/j.jns.2016.06.035
4. Hirst C, Swingler R, Compston DA, et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry. 2008;79(9):1016-21. doi: 10.1136/jnnp.2007.127332
5. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis : A Review. JAMA. 2021 Feb 23;325(8):765-79. doi: 10.1001/jama.2020.26858
6. Lunde HMB, Assmus J, Myhr KM, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621-5. doi: 10.1136/jnnp-2016-315238
7. Boyko AN, Kukel' TM, Lysenko MA, et al. Clinical epidemiology of multiple sclerosis in Moscow. Discriptive epidemiology in population of one region of Moscow. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10-2):8-14 (In Russ.).
8. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-31. doi: 10.1002/ana.410130302
9. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2
10. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. doi: 10.1212/WNL.0000000000000560
11. Demographic yearbook of Russia. 2023: Statistical digest. D31. Moscow: Rosstat; 2023. 256 p. (In Russ.). Available at: https://rosstat.gov.ru/folder/210/document/13207
12. Mortality of the population of the Republic of Bashkortostan: Statistical digest. Ufa: Bashkortostanstat; 2023. 128 p. (In Russ.). Available at: https://02.rosstat.gov.ru/folder/25491
13. Russian statistical yearbook. 2023 : Statistical digest. R76. Moscow: Rosstat; 2023. 701 p. (In Russ.). Available at: https://gogov.ru/articles/life-expectancy
14. Smyrke N, Dunn N, Murley C, et al. Standardized mortality ratios in multiple sclerosis : Systematic review with meta-analysis. Acta Neurol Scand. 2022;145(3):360-70. doi: 10.1111/ane.13559
15. Willumsen JS, Grytten N, Aarseth J, et al. Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study. J Neurol Neurosurg Psychiatry. 2022;93(11):1154-61. doi: 10.1136/jnnp-2022-329169
16. Coyle PK. What Can We Learn from Sex Differences in MS? J Pers Med. 2021;11(10):1006. doi: 10.3390/jpm11101006
17. Bsteh G, Bitschnau C, Hegen H, et al. Multiple sclerosis and COVID-19: How many are at risk? Eur J Neurol. 2021;28(10):3369-74. doi: 10.1111/ene.14555
18. Kuzmina USh, Tukhvatullin AV, Lyutov OV, et al. A case of COVID-associated encephalopathy in a patient with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):159-63 (In Russ.). doi: 10.17116/jnevro2024124041159
19. Fedeli U, Barbiellini AC, Avossa F, et al. Association of multiple-sclerosis-related mortality with COVID-19 and other common infections: a multiple causes of death analysis. Eur J Neurol. 2023;30(9):2870-3. doi: 10.1111/ene.15912
20. Sivertseva SA, Prilenskaya AM, Sivertsev MIu, et al. The risk of ischemic stroke in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8-2):88-94 (In Russ.). doi: 10.17116/jnevro201811808288
21. Zotov PB, Kucenko NI. Suicidal behavior in patients with multiple sclerosis (frequency, clinical forms, nature). Ural'skij medicinskij zhurnal. 2008;43(3):49-51 (In Russ.). Available at: http://elib.usma.ru/handle/usma/16842
22. Kutlubaev МА. Suicidal Behavior in Neurological Diseases: Frequency, Predictors and Prevention measures. Neurological Journal. 2016;21(3):124-30 (In Russ.). doi: 10.18821/1560-9545-2016-21-3-124-130
23. Kingwell E, Willumsen JS, Grytten N, et al. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study. J Neurol Neurosurg Psychiatry. 2022;93(11):1154-61. doi: 10.1136/jnnp-2022-329169
24. Koch-Henriksen N, Laursen B, Stenager E, et al. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry. 2017;88(8):626-31. doi: 10.1136/jnnp-2017-315907
25. Tukhvatullin AV, Kuzmina US, Utyagulova NF, et al. Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1S):15-20 (In Russ.). doi: 10.14412/2074-2711-2021-1S-15-20
26. Bezzini D, Kundisova L, Gori F, et al. Mortality trend for multiple sclerosis in Italy during the period 1980–2015. Mult Scler Relat Disord. 2020;44:102240. doi: 10.1016/j.msard.2020.102240
27. Leray E, Moreau T, Fromont A, et al. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006
28. Boytsov SA, Shalnova SA, Deev AD. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):98-103 (In Russ.). doi: 10.17116/jnevro201811808198
29. Harding K, Zhu F, Alotaibi M, et al. Multiple cause of death analysis in multiple sclerosis: A population-based study. Neurology. 2020;94(8):e820-e829. doi: 10.1212/WNL.0000000000008907
30. Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85(3):240-7. doi: 10.1212/WNL.0000000000001718
Review
For citations:
Lyutov OV, Kutlubaev MA, Kuzmina US, Akhmetgaleeva NF, Talipova ID, Bakhtiyarova KZ. The impact of multiple sclerosis on life expectancy (the experience of the Republic of Bashkortostan). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2026;18(1):49-56. (In Russ.) https://doi.org/10.14412/2074-2711-2026-1-49-56
Views:
350
JATS XML
Email this article 